<< Prev Study . Next Study >>

Characterizing a way to prevent drug-induced gastric pathology Pozen, Inc., wanted to determine how much gastric acidity had to be reduced by famotidine in order to prevent the gastroduodenal pathology caused by a particular nonsteroidal anti-inflammatory drug (NSAID). SFO answered this question for Pozen by calculating integrated acidity from gastric pH recordings from human subjects taking the NSAID. Defining the onset of action of a drug SFO also worked with Warner-Lambert Company (now Pfizer), to analyze gastric pH data from subjects being treated with a placebo, with famotidine (marketed by J&J-Merck) and with ranitidine (marketed by Warner-Lambert). The goal was to develop a method to determine the onset of action of the two drugs. Our analyses showed that the onset of action of the drug could be defined by the earliest time after dosing that the gastric pH was significantly different from that with placebo [View the details of the technique used and resultant findings in Reference 334.]